Results 61 to 70 of about 6,026 (204)

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, Volume 16, Issue 4, Page 751-765, April 2026.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

Real-world, multicentre evaluation of the incidence and risk factors for non-susceptible Stenotrophomonas maltophilia isolates [PDF]

, 2022
Background: Stenotrophomonas maltophilia is a cause of infection most commonly in the opportunistic host. Trimethoprim-sulfamethoxazole and levofloxacin are considered first-line treatment agents. With reports of increasing resistance to these first-line
Bookstaver, P. Brandon, Chastain, Daniel B., Jones, Bruce M., Wagner, Jamie L.   +3 more
core   +2 more sources

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) are associated with high mortality with limited treatment.
Davide Fiore Bavaro, Roberta Papagni, Alessandra Belati, Lucia Diella, Antonio De Luca, Gaetano Brindicci, Nicolò De Gennaro, Francesco Di Gennaro, Federica Romanelli, Stefania Stolfa, Luigi Ronga, Adriana Mosca, Francesco Pomarico, Maria Dell’Aera, Monica Stufano, Lidia Dalfino, Salvatore Grasso, Annalisa Saracino   +17 more
doaj   +1 more source

Cefiderocol Heteroresistance Associated With Mutations in TonB-Dependent Receptor Genes in Pseudomonas aeruginosa of Clinical Origin [PDF]

The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR) P. aeruginosa (PA). FDC circumvents traditional porin and efflux-mediated resistance by utilizing TonB-dependent receptors (TBDRs) to ...
Alcalde, Manuel, Arias, Cesar A, Baptista, Rodrigo P, Dinh, An Q, Egge, Stephanie L, Hakki, Morgan, Hanson, Blake M, Martinez, Jose R W, Miller, William R, Munita, Jose M, Rizvi, Samie A, Shelburne, Samuel A, Simar, Shelby R, Tran, Truc T   +13 more
core   +2 more sources

In vitro pharmacokinetics of cefiderocol alone and in combination with antibiotics against Achromobacter spp. and Stenotrophomonas maltophilia species

Journal of Global Antimicrobial Resistance
AIM: The point of this study was to compare and to contrast how well cefiderocol worked against a group of Achromobacter spp. and Stenotrophomonas maltophilia isolates in-vitro, both by itself and when mixed with other antibiotics.
Gokce Konyaoglu, Bekir Ozer, Bilge Sumbul, Mesut Yilmaz, Berna Ozbek Celik, Emel Mataraci Kara   +5 more
doaj   +1 more source

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples

Antibiotics, 2021
Background: Cefiderocol is a siderophore cephalosporin that exhibits antimicrobial activity against most multi-drug resistant Gram-negative bacteria, including Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas ...
Davide Carcione, Claudia Siracusa, Adela Sulejmani, Roberta Migliavacca, Alessandra Mercato, Aurora Piazza, Luigi Principe, Nicola Clementi, Nicasio Mancini, Valerio Leoni, Jari Intra   +10 more
doaj   +1 more source

An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 838-845, April 2026.
The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate ...
Yan Jin, Ashish Sharma, Mariam A. Ahmed, Sravanthi Cheeti, Ying Ou, Damayanthi Devineni, Yizhe Chen, Jitendra S. Kanodia, Yasmeen Abouelhassan, Nadia Noormohamed, Jin Zhou, Patrick Marroum, Vaishali Sahasrabudhe, Islam R. Younis   +13 more
wiley   +1 more source

An Assessment Of Cefiderocol's Synergistic Effects With Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime/Avibactam, And Tobramycin Against Carbapenem-Resistant Pseudomonas Aeruginosa

Journal of Global Antimicrobial Resistance
OBJECTIVES: This research examines the combined in vitro effectiveness of cefiderocol with other antibiotics against carbapenem-resistant Pseudomonas aeruginosa (CR-PA) obtained from Intensive Care Units.
Bekir Özer, Emel Mataraci Kara, Mesut Yılmaz, Berna Özbek Çelik   +3 more
doaj   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Mutation in the two-component regulator BaeSR mediates cefiderocol resistance and enhances virulence in Acinetobacter baumannii

mSystems, 2023
Acinetobacter baumannii has become one of the most challenging pathogens in many countries with limited treatment options available. Cefiderocol, a novel siderophore-conjugated cephalosporin, shows potent in vitro activity against A. baumannii, including
Xiaochen Liu, Yunjie Chang, Qingye Xu, Wang Zhang, Zhen Huang, Linyue Zhang, Shanshan Weng, Sebastian Leptihn, Yan Jiang, Yunsong Yu, Xiaoting Hua   +10 more
doaj   +1 more source